Samsung Biologics Secures $1.06 Billion Manufacturing Deal with US Pharma

Samsung Biologics voluntarily disclosed that it has secured a six-year deal with an unnamed U.S.-based pharmaceutical company, having secured a letter of intent signed in June. The contract runs through to the end of 2030.

In July 2023, Pfizer signed two long-term manufacturing deals with the Korean CDMO to produce biosimilars, worth $897 mn.

For more, please find the original story source here.